V-PRV131 + Radiation shows Dramatic Tumor Regression.
The patient - a 9-year old, 26 kg female Bernedoodle - was diagnosed with a rapidly growing, well differentiated fibrosarcoma with bony lysis, located in the upper jaw. The complexity and size of the tumor made surgery challenging, prompting the use of a combined therapeutic approach.
The dog received daily radiation therapy for three weeks, along with weekly intratumoral injections of V-PRV131, a novel nanoengineered cisplatin formulation developed for targeted local tumor treatment. The combination therapy led to significant tumor regression, reduction in volume, normalization of the tissue surface, and marked clinical improvement.
"The V-PRV131 injections enabled direct delivery of high-dose chemotherapy into the tumor, complementing the effects of radiation while preserving healthy surrounding tissues,” said Dr. Manijeh Goldberg, Founder and CEO of Privo Technologies. “These results reflect the power of localized oncology to transform outcomes in veterinary cancer care.”
Serial photographs show remarkable healing of the tumor site with minimal inflammation or damage to adjacent structures. The outcome reinforces the promise of V-PRV131 as a well-tolerated and effective treatment option for dogs with fibrosarcoma and other complex soft tissue sarcomas.
- Significant tumor volume reduction
- Restoration of tissue surface integrity
- Minimal damage to surrounding structures
- Enhanced quality of life
About PRV131
PRV131 is an injectable intratumoral formulation of cisplatin nanoparticles developed to deliver localized chemotherapy directly into tumors while minimizing systemic toxicity. It is currently under evaluation for both human and veterinary oncology indications and is a key asset within Privo’s proprietary PRV™ platform.
About BeneVet Oncology
BeneVet Oncology is the veterinary oncology division of Privo Technologies, focused on providing innovative cancer treatments for dogs and cats through localized drug delivery systems. In collaboration with veterinary oncologists nationwide, BeneVet is building a portfolio of therapies that prioritize animal comfort, safety, and long-term outcomes.
For more information, visit: https://www.bene-Vet.com